Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

Accelerated Reliance on Digital Animal Replacement Tech

Bio Spectrum

|

August 2025

While Europe is talking about non-animal replacement tests to be used for drug development and research purposes, US FDA is acting upon it with a detailed roadmap aimed at rapidly reducing animal testing in preclinical safety assessments. These developments clearly provide huge opportunities for global companies that are developing alternative methods such as organoids, 3D bioprinting, digital animal replacement technology, computer simulation, to name a few. But where does India stand in this regard, and how skilled are we to make this shift?

Accelerated Reliance on Digital Animal Replacement Tech

On April 29, the National Institutes of Health (NIH) in the US announced the adoption of a new initiative to expand innovative, human-based science while reducing animal use in research. In particular, the NIH intends to establish the Office of Research Innovation, Validation, and Application (ORIVA) to develop, validate, and scale the use of non-animal approaches across the agency’s biomedical research portfolio and serve as a hub for interagency coordination and regulatory translation for public health protection.

Developing and using cutting-edge non-animal research models very well aligns with the US Food and Drug Administration’s (FDA) recent initiative to reduce testing in animals.

imageSimultaneously, the European Medicines Agency (EMA) has released a revised draft paper that outlines non-animal replacement tests manufacturers can use to eliminate the use of animals in pharmaceutical testing. Further, the European Commission has confirmed plans to finalise its ‘Save Cruelty Free Cosmetics’ roadmap by early 2026, setting the stage for a gradual transition toward non-animal testing in chemical safety assessments.

Where does India stand in this scenario? Although an amendment to the New Drugs and Clinical Trial Rules (2023), passed by the Government of India in 2023, aimed to replace the use of animals in research, especially in drug testing, not much progress has been made so far. Indian regulatory bodies are still working out ways to strengthen the use of non-animal testing methods in laboratories across the country, as they are aware that completely eliminating animal models may not be a feasible process.

WEITERE GESCHICHTEN VON Bio Spectrum

Bio Spectrum

Bio Spectrum

India's Pharma Reforms Target Global Credibility

The Indian government has introduced several measures to simplify drug approvals and support innovation.

time to read

9 mins

October 2025

Bio Spectrum

Bio Spectrum

How Waste Management Strategies Can Transform Indian Pharma Manufacturing

Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.

time to read

7 mins

October 2025

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size